Bank of New York Mellon Corp boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.6% during the first quarter, Holdings Channel reports. The institutional investor owned 69,176 shares of the biopharmaceutical company’s stock after buying an additional 2,404 shares during the period. Bank of New York Mellon Corp’s holdings in Catalyst Pharmaceuticals were worth $135,000 at the end of the most recent quarter.

Separately, Candriam Luxembourg S.C.A. purchased a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at $1,170,000. Institutional investors own 29.79% of the company’s stock.

Shares of Catalyst Pharmaceuticals, Inc. (CPRX) traded down 4.56% during midday trading on Friday, hitting $2.72. 784,765 shares of the stock traded hands. The company’s 50 day moving average price is $2.88 and its 200-day moving average price is $1.98. Catalyst Pharmaceuticals, Inc. has a 12-month low of $0.74 and a 12-month high of $3.20. The stock’s market cap is $229.99 million.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, equities research analysts expect that Catalyst Pharmaceuticals, Inc. will post ($0.25) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/catalyst-pharmaceuticals-inc-cprx-position-increased-by-bank-of-new-york-mellon-corp.html.

CPRX has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.